Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
    Meeting Abstract

    Yau, T.; Meyer, T.; Kelley, R. K.; Mangeshkar, M.; Cheng, A. L.; El-Khoueiry, A. B.; Abou-Alfa, G. K.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI
    Meeting Abstract

    Han, J. Y.; Sequist, L. V.; Ahn, M. J.; Cho, B. C.; Yu, H.; Kim, S. W.; Yang, J. C. H.; Lee, J. S.; Su, W. C.; Kowalski, D.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
    Meeting Abstract

    Hyman, D.; Tan, D. S. W.; van Tilburg, C.; Albert, C.; Geoerger, B.; Farago, A.; Laetsch, T.; Kummar, S.; Doz, F.; Lassen, U.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial
    Meeting Abstract

    Oh, D. Y.; Golan, T.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Tepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study
    Meeting Abstract

    Park, K.; Felip, E.; Veillon, R.; Cortot, A.; Mazieres, J.; Sakai, H.; Reinmuth, N.; Viteri, S.; Chen, Y. M.; Han, J. Y.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
    Meeting Abstract

    Cohen, E.; Uppaluri, R.; Lee, N.; Westra, W.; Haddad, R.; Temam, S.; Le Tourneau, C.; Chernock, R.; Safina, S.; Tao, Y.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    Meeting Abstract

    de Braud, F.; Siena, S.; Barlesi, F.; Drilon, A.; Simmons, B.; Huang, X.; Osborne, S.; Doebele, R. C.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)
    Meeting Abstract

    Friedlander, M. L.; Moore, K. N.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Immunoscore predicts significant differences in time to recurrence in stage I colon cancer patients
    Meeting Abstract

    Galon, J.; Hermitte, F.; Mlecnik, B.; Marliot, F.; Bifulco, C.; Lugli, A.; Nagtegaal, I.; Hartmann, A.; van den Eynde, M.; Roehrl, M.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes based on albumin-bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Chan, S. L.; Miksad, R.; Cicin, I.; Chen, Y.; Klumpen, H. J.; Kim, S.; Lin, Z. Z.; Youkstetter, J.; Sen, S.; Cheng, A. L.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save